site logo
ARRS InPractice
  • Latest Issue
  • Contact Us
Homepage > Articles > Acute Ischemic Stroke: Treatment and Imaging Updates

Acute Ischemic Stroke: Treatment and Imaging Updates

codestrokeip

Published January 4, 2022

avatar

Jeremy J. Heit

Assistant Professor Departments of Radiology and Neurosurgery
Center for Academic Medicine Stanford University

    Acute ischemic stroke (AIS) results from occlusion of a cervical or cerebral artery, and it is the leading cause of disability in the US. The most severe forms of AIS result from thrombo- or thromboembolic occlusion of the internal carotid artery or proximal (M1 segment) of the middle cerebral artery, and these occlusions are termed large vessel occlusions (LVOs). LVOs are amenable to thrombectomy, which is a minimally invasive endovascular surgery that removes the thrombus from the affected artery (Fig. 1).

    Fig. 1—59-year-old male with atrial fibrillation developed sudden onset of left facial droop, left hemiplegia, dysarthria, and right-sided gaze preference (National Institutes of Health Stroke Scale score: 16). Emergent brain imaging was performed that demonstrated hypodensity in right lentiform nucleus (A, arrow) on non-contrast head CT, large vessel occlusion of M1 segment of right middle cerebral artery on CTA (B, arrow), small ischemic core on CT perfusion imaging (C, pink region indicated by arrow), and salvageable penumbra on CT perfusion imaging (D, dashed outline). Patient was transferred to neuroendovascular suite, and digital subtraction cerebral angiogram confirmed right M1 occlusion (E, arrow). Thrombectomy was performed, which resulted in complete revascularization of right middle cerebral artery (F, arrow). After remarkable recovery, patient had no residual symptoms three months posttreatment.

    Thrombectomy treatment of AIS due to LVO has exploded, following the publication of multiple randomized trials that demonstrated superior outcomes with thrombectomy treatment in patients presenting in both early (0–6 hours from last known well) and late (6–24 hours from last known well) time windows. These studies not only found thrombectomy to be superior to medical treatment, but they also fundamentally changed the evaluation and treatment triage of AIS-LVO patients.

    Previously, the best medical therapy for AIS was intravenous thrombolysis with tissue plasminogen activator (tPA), but tPA treatment was limited to patients who present within 3–4.5 hours from symptom onset. The time-sensitive nature of tPA treatment was a significant barrier, and it limited the number of patients eligible for treatment. The success of the thrombectomy trials has shattered the stopwatch that governs tPA treatment in LVO patients, and we have now entered an era in which imaging guides stroke treatment, rather than the time from symptom onset.

    The imaging evaluation of AIS patients has moved beyond the non-contrast head CT (NCCT) that has guided intravenous thrombolysis treatment decisions since 1995. Thrombectomy has the greatest impact when it is performed in a patient with minimal ischemic brain injury and an LVO, and these patients are identified at a minimum with an NCCT and a CT angiogram (CTA). Most of the index randomized thrombectomy trials also used CT perfusion (CTP) to characterize brain tissue that was likely permanently injured (the ischemic core) and the presence of underperfused, but salvageable, brain tissue (the penumbra). Due to the success of these trials, there has been a marked increase in CTP utilization for the evaluation of AIS patients with LVO. The increased use of CTA and CTP is making a meaningful impact on stroke treatment, but this usage has the potential to significantly strain radiology practice resources, given that AIS LVO patients should be screened for thrombectomy candidacy up to 24 hours after they were last known to be well.

    The need for timely evaluation of AIS patients and the increased utilization of CTA and CTP is being aided by the integration of automated image processing and artificial intelligence (AI) techniques that identify thrombectomy treatment candidates. The emergence and implementation of these disruptive software platforms has integrated into clinical practice at a pace seldom seen in medicine, demonstrating the potential value of AI to the practice of radiology.

    The success of thrombectomy and the increased use of CTA and advanced brain imaging, such as CTP, requires that radiologists are well aware of AIS patient evaluation and treatment workflows. Apropos, A RRS is offering an exciting and timely Sunday Featured Session with leading stroke experts during the 2022 Annual Meeting in New Orleans, LA. Join us for “Code Stroke: What Every Radiologist Should Know Early.”


    The opinions expressed in InPractice magazine are those of the author(s); they do not necessarily reflect the viewpoint or position of the editors, reviewers, or publisher.

    Related

    Previous StoryFinding Our Proverbial Sunrooms
    Next StoryPass or Fail? How a USMLE Update Could Change Radiology Residency

    ARRS

    Contact InPractice
    Meetings
    Articles with Credit
    Books / Books with Credit
    Online Courses
    Web Lectures

    AJR

    AJR Journal
    AJR Articles with Credit
    Subscribe to AJR

    ARRS Membership

    Benefits
    Join / Renew
    Volunteer Opportunities
    In-Training Radiologists
    Senior Radiologists

    Scholarships

    Donate Now
    Roentgen Fund®
    Fellowships / Awards
    Making a Difference

    The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians. ARRS has been granted Deemed Status by the American Board of Radiology (ABR). Copyright ©, American Roentgen Ray Society, ARRS, All Rights Reserved.